Physician profile
Ray Wilt
NPI 1770757692
$3,389.74
in general payments reported to CMS, 2019-2025
21 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $144 · 2021: $159 · 2022: $436 · 2023: $444 · 2024: $448 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $923.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $302.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.59 | 2019-2024 | Jardiance |
| Pfizer INC. | $273.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $204.31 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $184.99 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $161.10 | 2019-2025 | Wegovy |
| Esperion Therapeutics, INC. | $159.07 | 2021 | |
| Amgen INC. | $157.14 | 2019-2020 | |
| Boston Scientific Corporation | $148.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.50 | 2023 | |
| Allergan, INC. | $123.84 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.53 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.12 | 2019 | |
| Lilly USA, LLC | $41.78 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.77 | 2019 | |
| Shire North American Group INC | $32.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.27 | 2019 | |
| Dynavax Technologies Corporation | $16.81 | 2019 | |
| Merck Sharp & Dohme LLC | $16.13 | 2019 | |
| Astellas Pharma US INC | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Wilt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.